Large Cap Biopharmaceutical Update: Mixed Performance as Tariffs Loom…Update-2…4/29…Good gains in pharma and medtech

Update-2..4/29...3p EDT...Novartis (NVS) stock up over 1% on earnings beat raised guidance. Broad pipeline in four therapeutic areas. Good value with FWD PE of 14.9,PS of 4.3, Div.of 3.5%, RSI trending up. Added to stock today. Strong momentum in pharma, medtech, even Pfizer up 4% with 7%...

Bear Market Rally Spurs Biotech Stocks: A Primer on Tariffs…Update-3…Pivot Day Confirmed

Update-3 ...ABBVIE (ABBV) beat with adj. EPS 2.46 earnings and revenues of $13.343B  an increase of 4%, but tariff issues lurking,,, I$10M investments will be made in U.S. Strong sales $6.264B of new immunology drugs Rinvoq and Skirizi an increase of 16.6%.  EPS guidance raised to $12.09-12.29....

Is it a Good Time to Trade Small Cap Biotech Stocks?– 3 Steps to Consider…Update-3 …How do NIH cutbacks affect ongoing clinical trials?

UPDATE 4/15/25: Nice Rally in SMID BiOTECH on Monday then faded. UPDATE tomorrow with UNH Congress needs to do their job and prioritize cancer research funding especially for clinical trials. Update-3 4/13...We will summarize market performance for healthcare and biotech on our next update: XLV...

Pin It on Pinterest